Abstract: A semiconductor device (100) according to the present invention includes a thin film transistor (10) having a gate electrode (62a), a first insulating layer (64), an oxide semiconductor layer (66a), a protection layer (68), a source electrode (72as), and a second insulating layer (74). A first connecting portion (30) includes a lower metal layer (72c), an upper metal layer (72c), and an insulating layer (74). A second connecting portion (40) includes a lower metal layer (72d) and an upper conductive layer (17d). A region in which the lower metal layer (72d) is in contact with the upper conductive layer (17d), and a region in which an insulating layer (74) made of a same material as the first insulating layer and a semiconductor layer (66d) made of a same material as the oxide semiconductor layer (66a) are stacked in between the lower metal layer (72d) and the upper conductive layer (17d), are formed in the second connecting portion (40).

Abstract: The present invention is directed to substituted pyridizinone compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

Abstract: A TFT substrate (20) forming a part of a liquid crystal display panel includes: respective pixels having mutually adjacent first sub-pixels and second sub-pixels; first source electrodes (14aba) that branch towards the first sub-pixels and form a portion of respective first TFTs (5a) after respective source lines (14a) between the respective pixels continue along respective gate lines (11a) extending between the first sub-pixels and second sub-pixels of the respective pixels; and a second source electrode (14abb) that branches towards the second sub-pixel and forms a portion of the respective second TFTs (5b). The respective gate lines (11a) have openings where the respective source lines (14a) have branched.

Abstract: A touch sensor system includes a driver which drives on the basis of code sequences which are orthogonal to one another and include +1 or ?1 and each of which has a length N. A decoding section estimates on the basis of a first inner product operation of the outputs and the code sequences a first capacitance value and on the basis of a second inner product operation of the outputs and the code sequences a second capacitance value. A touch panel has a two-dimensional region including a hand placing region and a remainder region and processing sections.

Abstract: This invention relates to pyrazolopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.

Abstract: In a composite semiconductor device which is provided with a normally-on-type first transistor and a normally-off-type second transistor which are serially connected, the second transistor is selected so as to satisfy Formula (1): C oss > C ds ? V ds V br - C ds - C gs ( 1 ) In this regard: Coss: output capacitance of second transistor Cds: drain to source capacitance of first transistor Cgs: gate to source capacitance of first transistor Vds: power supply voltage Vbr: breakdown voltage of second transistor.

Abstract: A terminal includes a transmission unit which transmits HARQ response information to transmission of a downlink-shared channel in one or more predetermined subframes based on resources of one or more uplink control channels. When a certain subframe in the predetermined subframes is a first subframe, a resource of an uplink control channel is given by an arithmetic operation using at least an initial value of a control channel element for use in transmitting a physical downlink control channel in the certain subframe and a first value configured by a higher layer. When a certain subframe in the predetermined subframes is a second subframe, a resource of an uplink control channel is given by an arithmetic operation using at least an initial value of a control channel element for use in transmitting a physical downlink control channel in the certain subframe and a second value configured by a higher layer.

Abstract: In a light-source device (10) of this invention, integrated light emission intensity from 460 nm to 500 nm is higher than integrated light emission intensity from 415 nm to 460 nm in an emission spectrum of white light. This allows provision of a light-source device which emits white light easy on a human eye.

Abstract: By using a light emitting device including an insulating substrate and a light emitting unit formed on the insulating substrate, the light emitting unit including: a plurality of linear wiring patterns disposed on the insulating substrate in parallel with one another, a plurality of light emitting elements that are mounted between the wiring patterns while being electrically connected to the wiring patterns, and a sealing member for sealing the light emitting elements, as well as a method for manufacturing thereof, it becomes possible to provide a light emitting device that achieves sufficient electrical insulation and has simple manufacturing processes so that it can be manufactured at a low cost, and a method for manufacturing the same.

Abstract: The present invention provides a method for producing an organic EL element capable of shortening the film formation time while suppressing an increase in the blur width; and an organic EL display device.

Abstract: A front-end image acquisition component acquires photographs and/or videos of various goods, vehicles, vessels, and/or real estate fixtures. In one aspect, an image acquisition system comprises a hub with outwardly extending arms and supports for coupling to an upper support structure. Cameras are affixed to the hub and the arms for acquiring image data of a subject substantially simultaneously.

Abstract: A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.

Abstract: An amount of control information per subframe is reduced by keeping the amount of control information constant in both a case where multi-subframe scheduling is performed and a case where multi-subframe scheduling is not performed.

Abstract: An erroneous operation is prevented in a display device detecting a touch operation for a display face and a part other than the display face. A display device (1) of the present invention includes: an operation acquiring unit (51) that acquires detection signals transmitted from detection electrodes arranged on a touch panel (14); a use form determining unit (55) that determines a holding form based on a touch position of the touch operation for an end face of the display device; and an insensitive area setting unit (58) that sets an insensitive area on the operation detecting member after the holding form is determined. The operation acquiring unit does not acquire detection signals transmitted from the detection electrodes included in the set insensitive area among the detection electrodes.

Abstract: Provided are a frequency channel allocating section (10) that allocates frequency channels, a terminal reception quality information processing section (6) that calculates an optimal modulation rate and required transmit power for each subcarrier, a subcarrier power control section (12) that controls a level of transmit power for each subcarrier, and a determining section (10) that checks a reception bandwidth of a communicating apparatus, while determining whether the communicating apparatus is a full band terminal capable of receiving all the frequency channels in the system band or is a limited band terminal capable of receiving only part of frequencies, and when the communicating apparatus is the limited band terminal, the transmit power of all or part of subcarriers is decreased in a frequency channel that is adjacent to a reception band allocated to the communicating apparatus and that is allocated to another communicating apparatus.

Abstract: The present invention relates to compounds of formula I that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Abstract: The present disclosure provides a method performed by a base station. The method comprises: generating and transmitting a Physical Random Access Channel (PRACH) configuration parameter for a User Equipment (UE); detecting a random preamble sequence and/or a corresponding PRACH resource set transmitted from the UE, so as to determine a type and/or a coverage enhancement level of the UE; and generating a Random Access Response (RAR) based on the type and/or the coverage enhancement level of the UE. The present disclosure also provides a method performed by a UE and correspondingly a base station and a UE. With the present disclosure, it is possible to increase resource utilization for LTE to support MTC UEs, improve frequency spectrum/energy efficiency, and reduce time/frequency resource conflicts between cells.

Abstract: Compounds of Formula I: are HIV reverse transcriptase inhibitors, wherein R1, R2, RE, L, M and Z are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.